Leukemia Clinical Trials in North Carolina

Showing 781-800 of 1,759 trials

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

NCT02949843

This phase II trial studies how well targeted therapy works in treating patients with incurable non-small cell lung cancer with a genetic mutation. Giving drugs that target other genetic mutations or other specific proteins may work better when a patient has cancer caused by a driver mutation and the treatment that targets that mutation stops working.

EGFR Activating MutationRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer

Wake Forest University Health Sciences19 participantsStarted Mar 2017

Winston-Salem, North Carolina, United States

TERMINATEDPhase 241 miles

Efficacy of Ginseng for Patients on Regorafenib

NCT02581059

This is a randomized, multi-center phase II study of ginseng in colorectal cancer patients treated with regorafenib to determine if ginseng will reduce fatigue in this patient population and improve adherence to regorafenib. Ninety (90) subjects will be enrolled and randomized using a 2:1 allocation, with 60 subjects enrolled in the regorafenib + ginseng group and 30 enrolled in the regorafenib + no ginseng group.

Colorectal CancerPalliative MedicineSupportive Care

Wake Forest University Health Sciences10 participantsStarted Apr 2016

Indianapolis, Indiana, United States • Indianapolis, Indiana, United States • Morristown, New Jersey, United States +2 more locations

COMPLETEDNA46 miles

GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses

NCT03819569

Purpose: The purpose of this study is to evaluate the role of renal mass biopsy on decision-making for patients presenting with clinical T1 kidney tumors. This study also incorporates integrated biomarker study to compare the genomic data obtained through biopsy tissue to genomic information from surgical data.

Small Renal MassKidney Tumor

UNC Lineberger Comprehensive Cancer Center265 participantsStarted Oct 2018

Chapel Hill, North Carolina, United States

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Efficacy of Ginseng for Patients on Regorafenib

GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses

Leukemia Trials in Other Cities

House Dust Mite Allergy Trial In Children

Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study

Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Other Conditions in North Carolina